Boston Scientific agrees to pay an undisclosed amount to settle patent infringement cases against OrbusNeich in the U.S. and Europe over coronary stent technology.

Boston Scientific (NYSE:BSX) agreed to pay an undisclosed amount to put its long-running patent war with OrbusNeich Medical to rest.

The settlement covers patent infringement cases over coronary stent technology in the U.S., the U.K., Germany and Holland, according to an OrbusNeich press release.

“The agreement, which includes a one-time payment from Boston Scientific to OrbusNeich, settles all stent-related disputes between the companies and does not include future financial obligations,” according to the release.